Biotechnology News

Die Phase-I/II-Studie RESTORE-MASH wird die Sicherheit, Pharmakokinetik und Pharmakodynamik von TGM-312 bei gesunden Probanden und MASH-Patienten untersuchen Erste Daten werden für das zweite...

L’essai RESTORE-MASH de phase I/II évaluera la sécurité, la pharmacocinétique et la pharmacodynamique du TGM-312 chez des volontaires en bonne santé et des patients atteints de MASH Les premières...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of...

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...

MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced...

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary...

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74 Phase 1 dose escalation trial update planned...

Ervaren Life Sciences-manager treedt in dienst bij Galapagos met een bewezen trackrecord in change management Mechelen, België; 5 maart 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG)...

Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announced...